Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 12, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,370.56 pence per share.
- Treasury Shares Held: 240,732,678 shares (post-transaction).
- Shares in Issue: 5,752,573,715 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. The company acquired 550,000 shares on January 12, 2007, which are now held in Treasury. Consequently, the total number of shares in issue (representing total voting rights) remains 5,752,573,715, while the Treasury holding increased to 240,732,678.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,752,573,715) for calculating ownership thresholds under Financial Services Authority Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (240,732,678) for accurate fully diluted share count calculations.
- Note the specific execution price of 1,370.56 pence per share for the January 12, 2007 transaction.